Framingham, Mass., October 29, 2008-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) (“GTC”) will release its third quarter 2008 financial results on Monday, November 3, 2008 followed by a webcast conference call starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived webcast on GTC’s website at http://www.gtc-bio.com, or access the conference call as follows:
Live Call – In the United States, dial 1-888-679-8040
Outside the United States, dial 617-213-4851
Reference call ID: when prompted 58029637
Audio Archive – In the United States, dial 1-888-286-8010
Outside the United States, dial 617-801-6888
Reference call ID: when prompted 95435088
Participants may pre-register for the call at:
https://www.theconferencingservice.com/prereg/key.process?key=PB9CEVWA4
Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.
NOTE: the audio archive replay of the call will be available one hour following the end of the call and will be accessible until December 2, 2008. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About GTC Biotherapeutics, Inc.GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC’s recombinant human antithrombin, has been approved for use in Europe and has begun the review process in the United States under a Biologics License Application. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications and Government Relations
(508) 370-5374 or tom.newberry@gtc-bio.com
Copyright 2008 GTC Biotherapeutics, All Rights Reserved